Avalo Therapeutics (AVTX) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Avalo Therapeutics (AVTX) has outperformed Pharming Group N.V. (PHAR) over the past year, gaining 0.7% versus a loss of 34.2%. Over five years, PHAR leads with a +2.2% price change compared with -99.8% for AVTX. Avalo Therapeutics is the larger company by market cap ($728.3 million vs $683.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | PHAR |
|---|---|---|
| Share price | $13.58 | $9.65 |
| Market cap | $728.30M | $683.01M |
| 1-day change | -0.07% | -0.31% |
| YTD return | -25.22% | -45.39% |
| 1-year return | +0.74% | -34.22% |
| 5-year return | -99.79% | +2.22% |
| P/E ratio (TTM) | — | 74.23 |
| Forward P/E | — | 31.43 |
| EPS (TTM) | $-4.31 | $0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.27 | $21.34 |
| 52-week low | $12.51 | $9.59 |
| Distance from 52-week high | -44.05% | -54.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +224.59% | +255.96% |
| Average volume | 929.44K | 23.12K |
| Shares outstanding | 53.63M | 70.78M |
| Employees | 33 | 407 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVTX has outperformed PHAR by 35.0 percentage points over the past year.
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Healthcare · Biotechnology · 33 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Healthcare · Biotechnology · 407 employees
AVTX vs PHAR FAQ
Which is bigger, Avalo Therapeutics or Pharming Group N.V.?
Avalo Therapeutics (AVTX) is larger, with a market capitalization of $728.30M compared with $683.01M for Pharming Group N.V. (PHAR).
Which stock has performed better over the past year, AVTX or PHAR?
AVTX returned +0.74% over the past 12 months, compared with -34.22% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Pharming Group N.V. in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.